| abstract |
Vaccine compositions and methods of use are described herein. In one embodiment, the vaccine composition comprises RSV-F protein in combination with an adjuvant. In a more specific embodiment, the vaccine composition comprises RSV soluble F protein in combination with a lipid Toll-like receptor (TLR) agonist. In a more specific embodiment, the adjuvant comprises glucopyranosyl lipid A (GLA). In another embodiment, the adjuvant comprises GLA (GLA-SE) in a stable oil-in-water emulsion. [Selection] Figure 1A-B |